Cargando…

Aerosol Delivery of Palivizumab in a Neonatal Lamb Model of Respiratory Syncytial Virus Infection

(1) Background: Palivizumab has been an approved preventative monoclonal antibody for respiratory syncytial virus (RSV) infection for over two decades. However, due to its high cost and requirement for multiple intramuscular injections, its use has been limited mostly to high-income countries. Follo...

Descripción completa

Detalles Bibliográficos
Autores principales: Edirisinghe, Hasindu S., Rajapaksa, Anushi E., Royce, Simon G., Sourial, Magdy, Bischof, Robert J., Anderson, Jeremy, Sarila, Gulcan, Nguyen, Cattram D., Mulholland, Kim, Do, Lien Anh Ha, Licciardi, Paul V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675108/
https://www.ncbi.nlm.nih.gov/pubmed/38005952
http://dx.doi.org/10.3390/v15112276
_version_ 1785149783014375424
author Edirisinghe, Hasindu S.
Rajapaksa, Anushi E.
Royce, Simon G.
Sourial, Magdy
Bischof, Robert J.
Anderson, Jeremy
Sarila, Gulcan
Nguyen, Cattram D.
Mulholland, Kim
Do, Lien Anh Ha
Licciardi, Paul V.
author_facet Edirisinghe, Hasindu S.
Rajapaksa, Anushi E.
Royce, Simon G.
Sourial, Magdy
Bischof, Robert J.
Anderson, Jeremy
Sarila, Gulcan
Nguyen, Cattram D.
Mulholland, Kim
Do, Lien Anh Ha
Licciardi, Paul V.
author_sort Edirisinghe, Hasindu S.
collection PubMed
description (1) Background: Palivizumab has been an approved preventative monoclonal antibody for respiratory syncytial virus (RSV) infection for over two decades. However, due to its high cost and requirement for multiple intramuscular injections, its use has been limited mostly to high-income countries. Following our previous study showing the successful lung deposition of aerosolised palivizumab in lambs, this current study evaluated the “proof-of-principle” effect of aerosolised palivizumab delivered as a therapeutic to neonatal lambs following RSV infection. (2) Methods: Neonatal lambs were intranasally inoculated with RSV-A2 on day 0 (day 3 post-birth) and treated with aerosolised palivizumab 3 days later (day 3 post-inoculation). Clinical symptoms, RSV viral load and inflammatory response were measured post-inoculation. (3) Results: Aerosolised therapeutic delivery of palivizumab did not reduce RSV viral loads in the nasopharynx nor the bronchoalveolar lavage fluid, but resulted in a modest reduction in inflammatory response at day 6 post-inoculation compared with untreated lambs. (4) Conclusions: This proof-of-principle study shows some evidence of aerosolised palivizumab reducing RSV inflammation, but further studies using optimized protocols are needed in order to validate these findings.
format Online
Article
Text
id pubmed-10675108
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106751082023-11-19 Aerosol Delivery of Palivizumab in a Neonatal Lamb Model of Respiratory Syncytial Virus Infection Edirisinghe, Hasindu S. Rajapaksa, Anushi E. Royce, Simon G. Sourial, Magdy Bischof, Robert J. Anderson, Jeremy Sarila, Gulcan Nguyen, Cattram D. Mulholland, Kim Do, Lien Anh Ha Licciardi, Paul V. Viruses Brief Report (1) Background: Palivizumab has been an approved preventative monoclonal antibody for respiratory syncytial virus (RSV) infection for over two decades. However, due to its high cost and requirement for multiple intramuscular injections, its use has been limited mostly to high-income countries. Following our previous study showing the successful lung deposition of aerosolised palivizumab in lambs, this current study evaluated the “proof-of-principle” effect of aerosolised palivizumab delivered as a therapeutic to neonatal lambs following RSV infection. (2) Methods: Neonatal lambs were intranasally inoculated with RSV-A2 on day 0 (day 3 post-birth) and treated with aerosolised palivizumab 3 days later (day 3 post-inoculation). Clinical symptoms, RSV viral load and inflammatory response were measured post-inoculation. (3) Results: Aerosolised therapeutic delivery of palivizumab did not reduce RSV viral loads in the nasopharynx nor the bronchoalveolar lavage fluid, but resulted in a modest reduction in inflammatory response at day 6 post-inoculation compared with untreated lambs. (4) Conclusions: This proof-of-principle study shows some evidence of aerosolised palivizumab reducing RSV inflammation, but further studies using optimized protocols are needed in order to validate these findings. MDPI 2023-11-19 /pmc/articles/PMC10675108/ /pubmed/38005952 http://dx.doi.org/10.3390/v15112276 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Edirisinghe, Hasindu S.
Rajapaksa, Anushi E.
Royce, Simon G.
Sourial, Magdy
Bischof, Robert J.
Anderson, Jeremy
Sarila, Gulcan
Nguyen, Cattram D.
Mulholland, Kim
Do, Lien Anh Ha
Licciardi, Paul V.
Aerosol Delivery of Palivizumab in a Neonatal Lamb Model of Respiratory Syncytial Virus Infection
title Aerosol Delivery of Palivizumab in a Neonatal Lamb Model of Respiratory Syncytial Virus Infection
title_full Aerosol Delivery of Palivizumab in a Neonatal Lamb Model of Respiratory Syncytial Virus Infection
title_fullStr Aerosol Delivery of Palivizumab in a Neonatal Lamb Model of Respiratory Syncytial Virus Infection
title_full_unstemmed Aerosol Delivery of Palivizumab in a Neonatal Lamb Model of Respiratory Syncytial Virus Infection
title_short Aerosol Delivery of Palivizumab in a Neonatal Lamb Model of Respiratory Syncytial Virus Infection
title_sort aerosol delivery of palivizumab in a neonatal lamb model of respiratory syncytial virus infection
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675108/
https://www.ncbi.nlm.nih.gov/pubmed/38005952
http://dx.doi.org/10.3390/v15112276
work_keys_str_mv AT edirisinghehasindus aerosoldeliveryofpalivizumabinaneonatallambmodelofrespiratorysyncytialvirusinfection
AT rajapaksaanushie aerosoldeliveryofpalivizumabinaneonatallambmodelofrespiratorysyncytialvirusinfection
AT roycesimong aerosoldeliveryofpalivizumabinaneonatallambmodelofrespiratorysyncytialvirusinfection
AT sourialmagdy aerosoldeliveryofpalivizumabinaneonatallambmodelofrespiratorysyncytialvirusinfection
AT bischofrobertj aerosoldeliveryofpalivizumabinaneonatallambmodelofrespiratorysyncytialvirusinfection
AT andersonjeremy aerosoldeliveryofpalivizumabinaneonatallambmodelofrespiratorysyncytialvirusinfection
AT sarilagulcan aerosoldeliveryofpalivizumabinaneonatallambmodelofrespiratorysyncytialvirusinfection
AT nguyencattramd aerosoldeliveryofpalivizumabinaneonatallambmodelofrespiratorysyncytialvirusinfection
AT mulhollandkim aerosoldeliveryofpalivizumabinaneonatallambmodelofrespiratorysyncytialvirusinfection
AT dolienanhha aerosoldeliveryofpalivizumabinaneonatallambmodelofrespiratorysyncytialvirusinfection
AT licciardipaulv aerosoldeliveryofpalivizumabinaneonatallambmodelofrespiratorysyncytialvirusinfection